© 2004 by Oxford University Press and the Maryland Psychiatric Research Center (MPRC)
The International Suicide Prevention Trial (InterSePT): Rationale and Design of a Trial Comparing the Relative Ability of Clozapine and Olanzapine To Reduce Suicidal Behavior in Schizophrenia and Schizoaffective Patients
Pfizer Global Research and Development Ann Arbor, MI
Basle Switzerland
Novartis Pharmaceuticals East Hanover, NJ
Vanderbilt University Nashville, TN
Psychiatric Research, Long Island Jewish-Hillside Medical Center Glen Oaks, NY
Department of Psychiatry, Duke University Durham, NC
Department of Psychiatry, Dartmouth University Hanover, NH
Department of Psychiatry, University of California Irvine, CA
McGill University Montreal, Canada
Manhattan Psychiatric Center-Nathan Kline Institute for Psychiatric Research Wards Island, NY
Kings College, Institute of Psychiatry London, England
Send reprint requests to Dr. L. Alphs, 765 Watershed Court, Ann Arbor, MI 48105; e-mail: larry.alphs{at}pfizer.com
Suicidal behavior in patients with psychotic disorders represents a seriously undertreated life-threatening condition. The International Suicide Prevention Trial (InterSePT) is the first large-scale, prospective study designed to evaluate the potential of antipsychotic medications to reduce suicidal behaviors in patients with schizophrenia or schizoaffective disorder who are known to be at high risk for suicide. The unique challenges to study design and the solutions identified for the InterSePT study are described. These challenges included defining suicidal behavior in patients with psychosis, endpoint selection, determination of analytic strategy, and development of scales to assess suicidal behavior. Given the life-threatening nature of suicidal behavior, ethical considerations required that the design minimize suicide attempts and deaths. While the study focused primarily on treatment of suicide, opportunities were used to collect data in related areas of interest, including suicide risk factors, other efficacy measures (e.g., Positive and Negative Syndrome Scale, Covi Anxiety Scale, Calgary Depression Scale), adverse events, pharmacoeconomics, and pharmacogenetics. Because of the complexity of the design issues, a steering committee, suicide monitoring board, and publication committee were established to assist with their management.
Keywords: Suicide / suicidal behavior / schizophrenia / schizoaffective disorder / study design / clozapine / olanzapine
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R. Upthegrove Depression in schizophrenia and early psychosis: implications for assessment and treatment Adv. Psychiatr. Treat., September 1, 2009; 15(5): 372 - 379. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. B Dunn, P. J Candilis, and L. W. Roberts Emerging Empirical Evidence on the Ethics of Schizophrenia Research Schizophr Bull, January 1, 2006; 32(1): 47 - 68. [Abstract] [Full Text] [PDF]
|
|